ScoreComparison
Why is LSL Pharma Group, Inc. ?
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 77.00% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 6.95% signifying low profitability per unit of shareholders funds
2
Positive results in Jun 24
- NET PROFIT(HY) Higher at CAD -0.8 MM
- NET SALES(Q) Highest at CAD 4.19 MM
- RAW MATERIAL COST(Y) Fallen by -11.2% (YoY)
3
With ROE of 14.63%, it has a very attractive valuation with a 1.82 Price to Book Value
- Over the past year, while the stock has generated a return of -5.06%, its profits have risen by 157% ; the PEG ratio of the company is 0.1
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -5.06% returns in the last 1 year, the stock has also underperformed S&P/TSX 60 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to LSL Pharma Group, Inc. should be less than 10%
- Overall Portfolio exposure to Gems, Jewellery And Watches should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Gems, Jewellery And Watches)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is LSL Pharma Group, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
LSL Pharma Group, Inc.
-6.25%
-0.39
55.75%
S&P/TSX 60
19.1%
1.23
15.27%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
77.00%
EBIT Growth (5y)
109.95%
EBIT to Interest (avg)
-0.87
Debt to EBITDA (avg)
8.08
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.38
Tax Ratio
1.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.76%
ROE (avg)
6.95%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.82
EV to EBIT
57.35
EV to EBITDA
20.36
EV to Capital Employed
1.46
EV to Sales
2.73
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
2.55%
ROE (Latest)
14.63%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for LSL Pharma Group, Inc.
Net Sales
Highest at CAD 4.19 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Net Sales
At CAD 4.19 MM has Grown at 106.05%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CAD MM)
Net Profit
Higher at CAD -0.8 MM
than preceding 12 month period ended Jun 2024MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CAD MM)
Raw Material Cost
Fallen by -11.2% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for LSL Pharma Group, Inc.
Interest
At CAD 0.87 MM has Grown at 124.5%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CAD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
